Apogee Therapeutics, Inc. Common Stock (APGE) - Total Liabilities
Based on the latest financial reports, Apogee Therapeutics, Inc. Common Stock (APGE) has total liabilities worth $33.25 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Apogee Therapeutics, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Apogee Therapeutics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Apogee Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Apogee Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Apogee Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Simec S.A.B. de C.V
MX:SIMECB
|
Mexico | MX$11.97 Billion |
|
Crocs Inc
NASDAQ:CROX
|
USA | $2.92 Billion |
|
SIG Combibloc Group AG
SW:SIGN
|
Switzerland | CHF4.41 Billion |
|
Beijing Oriental Yuhong Waterproof Technology Co Ltd
SHE:002271
|
China | CN¥21.37 Billion |
|
Enphase Energy Inc
NASDAQ:ENPH
|
USA | $1.62 Billion |
|
MDA Space Ltd.
NYSE:MDA
|
USA | $1.40 Billion |
|
Umicore S.A.
BR:UMI
|
Belgium | €6.58 Billion |
|
Turk Telekomunikasyon AS
IS:TTKOM
|
Turkey | TL214.22 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Apogee Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Apogee Therapeutics, Inc. Common Stock stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 26.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apogee Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $33.25 Million | -10.51% |
| 2024-12-31 | $37.16 Million | +72.90% |
| 2023-12-31 | $21.49 Million | +115.34% |
| 2022-12-31 | $9.98 Million | -- |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treat… Read more